secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-06-08T10:32:15+00:00
Accession:  0001193125-26-260640
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan presents initial Phase 1 CLN-978 data in SLE and RA at EULAR; 71% SLE response rate, 5 DORIS remissions
--------------------------------------------------------------------------------

- In SLE (n=18), 10 of 14 patients (71%) with ≥4 weeks follow-up achieved ≥4-point hSLEDAI reduction; 5 attained DORIS remission.
- In RA (n=11), disease activity improved in 5 of 7 evaluable patients (71%), including one DAS28-ESR remission at 30 µg target dose.
- Peripheral B-cell depletion >80% in 82% of SLE patients; BLOQ depletion in 50% at target doses ≥20 µg. Dose-dependent depletion also seen in tissues.
- CRS events in 11 of 29 patients (38%); mostly Grade 1. One Grade 3 CRS at 45 µg dose led to cohort discontinuation; no ICANS observed.
- Company to host Immunology Day June 10 with additional CLN-978 multi-dose data and initial velinotamig data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526260640/0001193125-26-260640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526260640/cgem-20260606.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-260640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer